Content about Pulmonology

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for chronic obstructive pulmonary disease, the agency said Friday.

The FDA announced the approval of Breo Ellipta (fluticasone furoate and vilanterol), a once-per-day inhaler made by GlaxoSmithKline and Theravance for long-term treatment of COPD, which includes chronic bronchitis and emphysema.

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

WASHINGTON — A division of drug maker Teva Pharmaceutical Industries is partnering with an advocacy group focused on asthma in the launch of a new educational website about the condition.

The Asthma and Allergy Foundation of America and Teva Respiratory announced the launch of Get Smart About Asthma, which aims to increase understanding of how inflammation in the airways contributes to the disease's persistence and severity, as well as providing other educational materials.

NORTH WALES, Pa. — An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

The company, which is the branded respiratory division of Israeli drug maker Teva Pharmaceutical Industries, announced the available of ProAir HFA (i.e., albuterol sulfate), for patients aged 4 and older to prevent and treat bronchospasm with reversible obstructive airway disease and prevent exercise-induced bronchospasm. The inhaler received Food and Drug Administration approval in March 2012.

The November/December 2012 Cough, Cold and Flu Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Mucinex, Vicks, Advil, Theraflu, Delsym, St. Joseph, Hyland's Similasan and Zicam products.

Click here for the complete guide.

MARLBOROUGH, Mass. – The Food and Drug Administration has approved a drug made by Acton Pharmaceuticals for asthma, the company said Thursday.

The drug maker announced the approval of Aerospan (flunisolide HFA) inhalation aerosol as a maintenance treatment for asthma in patients aged 6 and older. The drug maker plans to launch the drug in early 2013.

LOS ANGELES — Earlier this summer Hyland’s introduced its Leg Cramps Ointment to complement its line of homeopathic Leg Cramps tablets. Expect the leg cramp market to grow. According to one study, about half of all seniors suffer from leg cramps — they’re more common in women (56%) than men (40%). And two drug classes with strong links to leg cramps include diuretics and the inhaled long-acting B2-agonists 
(e.g., Advair, Serevent, Symbicort).

ARLINGTON HEIGHTS, Ill. — According to the American College of Allergy, Asthma and Immunology, 25 million adults and children across the country were diagnosed with rhinitis, or hay fever, within the last 12 months, which may lead many to believe they’ve caught an early-season cold.

BASKING RIDGE, N.J. — Drug maker Mylan will pass out free EpiPen injectors to children in schools, the company said Tuesday.

Mylan Specialty, the Mylan unit that makes the EpiPen (epinephrine), announced the launch of the EpiPen4Schools program. The program offers four free EpiPen or EpiPen Jr. injectors to public and private school students in kindergarten, elementary, middle and high school, who have valid prescriptions.

ARLINGTON, Va. — Four-out-of-5 seasonal allergy sufferers reported their fitness regimens suffer because they exercise less or their performance isn't as strong, according to a survey released Thursday from AllergEase.

The survey also captured some of the social implications of being a seasonal allergy sufferer. Nearly 45% of people have turned down social invitations because of their seasonal allergies, the survey found, and 40% reported having had a vacation or getaway negatively affected by seasonal allergies.

Retailers are awakening to the possibility that their sleep aids — typically merchandised near the floor level of a set synergistically near tablet pain relievers — may deserve a placement closer to eye level. It may sound cliché to characterize sleep aids as a sleeper category — that is until you look at the 11.6% trailing 52-week dollar growth, and then back down to the floor where the sleep aids are typically merchandised.


WOONSOCKET, R.I. — CVS/pharmacy has announced the launch of a new in-store fundraising campaign, named Advancing Medical Research, to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis and cystic fibrosis.
 
Funds raised through the campaign will benefit the ALS Therapy Alliance, an organization dedicated to advancing ALS research, and the Cystic Fibrosis Foundation. Supporters for the 2012 campaign can donate $1 or $3 at the register in CVS/pharmacy locations and online through June 30.